Institutional Ownership
Zentalis Pharmaceuticals Inc
CUSIP 98943L107COMZNTLQ1 2026
13D / 13G Filings
69
Schedule 13D/13G on record
Beneficial Filers
24
Distinct reporting persons
Largest Stake
19.8%
Max % of class reported
Institutional Holders
97
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
69 filings · latest Mar 3, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 3, 2026 | Squadron Master Fund LP | 13G | 5.1% | 3.68M | SEC |
| 2 | Jan 5, 2026 | Walters William T | 13G/A | 19.7% | 13.51M | SEC |
| 3 | Jan 2, 2026 | Matrix Capital Management Company, LP | 13D/A | — | — | SEC |
| 4 | Dec 30, 2025 | 5am Opportunities II (Gp), LLC | 13G | 6.4% | 4.84M | SEC |
| 5 | Dec 15, 2025 | Matrix Capital Management Company, LP | 13D/A | 10.0% | — | SEC |
| 6 | Nov 12, 2025 | Barclays PLC | 13G | 5.3% | 3.84M | SEC |
| 7 | Oct 14, 2025 | Millennium Management LLC | 13G/A | 11.0% | 902.5K | SEC |
| 8 | Jul 16, 2025 | Blackrock, Inc. | 13G/A | 2.2% | 1.61M | SEC |
| 9 | May 14, 2025 | Eventide Asset Management, LLC | 13G/A | — | — | SEC |
| 10 | May 13, 2025 | Eventide Asset Management, LLC | 13G/A | — | — | SEC |
59 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Zentalis Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | 5am Venture Management, LLC | 3.95M | $9.24M |
| 2 | Squadron Capital Management LLC | 3.63M | $8.50M |
| 3 | Two Sigma Investments, LP | 2.96M | $6.92M |
| 4 | Renaissance Technologies LLC | 1.94M | $4.54M |
| 5 | Citadel Advisors LLC | 1.73M | $4.05M |
| 6 | D. E. Shaw & Co., Inc. | 1.48M | $3.47M |
| 7 | Opaleye Management Inc. | 1.41M | $3.31M |
| 8 | Decheng Capital LLC | 1.32M | $3.10M |
| 9 | Millennium Management LLC | 1.29M | $3.02M |
| 10 | Blackrock, Inc. | 1.27M | $2.97M |